Novavax Inc
NVAX
查看详细走势图
9.340USD
+0.080+0.86%
收盘 03/25, 16:00（美东）报价延迟15分钟
57.03M总市值
3.44市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.86%
5天
-6.69%
1月
-1.99%
6月
+11.99%
今年开始到现在
+38.99%
1年
+23.54%
查看详细走势图
TradingKey Novavax Inc股票评分
单位: USD 更新时间: 2026-03-25操作建议
Novavax Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名82/391位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价13.12。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Novavax Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Novavax Inc亮点
亮点风险
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值3.44，处于3年历史高位
机构减仓
最新机构持股103.32M股，环比减少4.45%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值175.80K
活跃度增加
近期活跃度增加，过去20天平均换手率0.03
分析师目标
根据
9
位分析师
持有
评级
13.125
目标均价
+35.03%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Novavax Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Novavax Inc简介
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
公司代码NVAX
公司Novavax Inc
CEOJacobs (John C)
网址https://www.novavax.com/?locale=US
相关品种
